Belfast, UK, 2 November 2022 – CV6 Therapeutics (‘CV6’), a drug development biotechnology company that specializes in innovative small molecule therapeutics for cancer and inflammatory diseases, announces it has secured $9.2m to progress the company’s lead oncology asset CV6-168 into a first-in-human Phase 1a clinical trial and perform further scientific development work. Investors participating in the financing […]

Belfast, UK. 5th January, 2021. CV6 Therapeutics, a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases,  have been featured in the November 2020 special report on the ‘12 Clusters of Tech’, a national campaign to champion leading clusters of UK technology led by the UK Tech Cluster […]

Belfast, UK. 4th January, 2021. CV6 Therapeutics, a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that they have been recognised as a Platinum Level Innovator by Innovate Northern Ireland on behalf of the Department of the Economy for Northern Ireland. The award was based […]

Belfast, UK. 15th March, 2019. CV6 Therapeutics Inc., a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that CEO and Founder Dr Robert Ladner has been invited to participate in the Europe CEO networking forum in Vienna, Austria on the 24th of March, 2019. Europe CEO is […]

Belfast, UK. 7th January, 2019. CV6 Therapeutics Inc., a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that it will be featured as a presenting company at Biotech Showcase™ 2019, to be held on the 7th-9th January at the Hilton San Francisco Union Square. […]

Belfast, UK. 25 September, 2018. CV6 Therapeutics (CV6), a drug development company focused on the development and commercialisation of novel combination therapeutics for cancer, today announced they would be presenting details on CV6-168, a novel anticancer therapeutic at the 30th EORTC/AACR/NCI Molecular Targets and Cancer Therapeutics Symposium in Dublin, Ireland on 16th of November 2018. The abstract […]

Belfast, U.K. – 18 September, 2018. CV6 Therapeutics (CV6), a drug development company focused on the development and commercialisation of novel combination therapeutics for cancer, announced today that Dr. Robert Ladner, CEO and Founder, was invited to present the Company’s ground-breaking research that led to the development of the novel dUTPase inhibitor and clinical drug […]

Belfast, UK. 17 May, 2018. Robert Ladner, CEO and Founder of CV6 Therapeutics Ltd (CV6), paid tribute today to Professor Patrick G. Johnston at a memorial symposium hosted by Queen’s University Belfast to honour and celebrate the life and accomplishments of “A Leader and Innovator in Cancer Research and Treatment”. Patrick, or ‘Paddy’ to those who […]

Belfast, U.K. – May 17, 2018. CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of two new members to their Scientific Advisory Board. Paul Workman, PhD, Chief Executive and President of The Institute of Cancer Research (ICR), London, UK. […]

Belfast, U.K. – March 19, 2018.  CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of Richard Milliken, CA as Chairman of the Board of Directors. “We are pleased to welcome Richard as our Board Chairman, his extensive experience […]